10 Top Stocks to Buy In November

The market shows mixed signals: strong year-to-date performance with green across the board, but also stretched valuations, increasing capex spending, and concerns about an AI bubble. A recent rate cut was positive, but future cuts are uncertain. Given rising uncertainty, being selective with investments is crucial, leading to the recommendation of 10 must-buy stocks for November.

S&P Global is up 1% over the last year, flat year-to-date, but has significantly outperformed the S&P 500 over 10 years. It's trading at the lower end of its 52-week range. Wall Street rates it a 'strong buy'. Its forward P/E of 26.8 is well below its historical 30, indicating potential undervaluation. The intrinsic price is estimated at $648, suggesting 33% upside. A reverse DCF shows 8.2% growth baked in, making it potentially undervalued if growth exceeds this.

Meta Platforms is up 11% over the last year. Despite a recent earnings-related drop, it remains a strong performer over 10 years. It's trading at the midpoint of its 52-week range, with Wall Street giving it a 'strong buy'. The forward P/E is 22, below its 5-year average of 23, suggesting potential undervaluation. The intrinsic value is $800, indicating 21% upside, with a 9.3% growth baked into the reverse DCF.

Automatic Data Processing is down 11% in the last year and year-to-date, trading at a 52-week low. It has marginally outperformed the S&P over 10 years. Wall Street rates it a 'hold'. Its forward P/E of 23.4 is a 5-year low, below its historical 28.6, signaling severe undervaluation. The intrinsic value is $316, with 4.8% growth baked in. Wall Street sees $310 for next year, a 19% upside.

Mondelez is down 17% over the last year and 5% year-to-date, underperforming the S&P over 10 years. It's near its 52-week low. Wall Street gives it a 'respectable buy'. Its forward P/E of 18.7 is one of its lowest in five years, below the historical average of 21. The dividend yield is also its highest at 3.5%. The intrinsic price is $69, suggesting an 18% margin of safety.

Mastercard is up 7% over the last year and 4% year-to-date, outperforming the S&P over 10 years. It trades at the midpoint of its 52-week range. Wall Street rates it a 'double buy'. Its forward P/E of 30 is below its historical average of 33. The intrinsic price is $637, with 11.8% growth baked in, suggesting 16% upside. Wall Street sees $650 next year, a 19% upside.

Booking Holdings is up 8% over the last year and 2% year-to-date, marginally outperforming the S&P over 10 years. It's trading at the midpoint of its 52-week range. Wall Street gives it a 'double buy'. Its forward P/E is below 20, historically at 22.2. Its PEG of 1.3 represents a significant discount to its sector and 5-year average. The intrinsic price is just under $6,000, and Wall Street sees $6185 next year, a 22% upside.

Novo Nordisk is down 57% over the last year, 43% year-to-date, but up 79% over 10 years. It's in a massive downward spiral and trading near its 52-week low. Wall Street rates it a 'weak buy'. Its forward P/E of 13.1 is the lowest in five years, significantly below its average of 30.4. The dividend yield is 3.6%, the highest in five years. The intrinsic value ranges from $46 to $72, depending on long-term outlook. Wall Street sees $68 next year, suggesting 42% upside.

Waste Management is down 7% over the last year, flat year-to-date, but has outperformed the S&P over 10 years. It's trading at its 52-week low. Wall Street gives it a 'singular buy' rating. Its forward P/E of 24.9 is in line with its lowest over the last 5 years, below its historical 27.6. The intrinsic value is $221. Wall Street estimates $250 next year, a 26% upside.

Elevance Health is down 22% over the last year and 14% year-to-date, with a downward trend since last summer, trading near its 52-week low. Wall Street rates it a 'double buy'. Its forward P/E of 11 is below its historical 13.8. The dividend yield is 2.2%, above its 5-year average. There is severe undervaluation noted, with an intrinsic value of $41, and Wall Street seeing $395 next year, a 23% upside.

Union Pacific is down 6% over the last year and 4% year-to-date, but up 154% over 10 years. It's trading towards the low end of its 52-week range. Wall Street gives it a 'double buy'. Its forward P/E is below 18, historically at 20. The yield of 2.5% is edging above its 5-year average. Undervaluation has been noted only a few times. The intrinsic price is $247, and Wall Street estimates $265 next year, a 22% upside.

Intuit is up 6% over the last year and 5% year-to-date, massively outperforming the S&P over 10 years. It's trading at the mid to lower end of its 52-week range. Wall Street gives it a 'respectable buy'. Its forward P/E of 28 is below its historical 34, signaling undervaluation. The intrinsic price is just under $800, and Wall Street is bullish at $835 next year, a 28% upside.